Compound Reference

PT-141

A melanocortin-receptor agonist · FDA-approved as Vyleesi (bremelanotide)

Melanocortin · sexual-health researchEvidence: Phase 3 (approved indication)FDA-approved (specific indication)

Approved — for a specific indication. Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women — prescription-only. "PT-141" sold as a research chemical is not the approved product. Educational only, not medical advice.

What it is

PT-141 (bremelanotide) is a melanocortin-receptor agonist derived from the melanotan lineage. Unlike PDE5 inhibitors (which act on blood flow), it works centrally in the brain.

Mechanism

It activates melanocortin-4 receptor (MC4R) — a GPCR involved in central pathways of sexual desire and arousal.² Acting on desire circuitry rather than vasculature is what distinguishes the melanocortin approach.¹

Evidence & status

Approved: FDA-approved (Vyleesi) for HSDD in premenopausal women, on Phase 3 evidence.¹
Common side effect: transient nausea; flushing.
The melanotan family also affects pigmentation — a reminder these receptors are pleiotropic.

References

Bremelanotide / PT-141 clinical literature. PubMed: bremelanotide
Kobilka, GPCR structure (MC4R is a GPCR) — Nobel review. Angew. Chem.

Explore the full library & 75-compound reference →

For educational and research purposes only. This content is not medical advice. Bremelanotide is a prescription drug; obtain and use medicines only under a licensed professional. Free Peptide University does not sell compounds.